Karolinska Development AB (publ) (KDEVF) Research

Karolinska Development AB (publ) operates as a venture capital firm, primarily focused on providing funding to nascent companies across seed, early, and growth stages. Its investment strategy targets a wide array of life science domains, including pharmaceutical and genetic research and development, medical advancements, healthcare technology, innovative drug delivery systems, biotechnology, and specialized tools and service providers for the life science industry. The company strategically prioritizes investment opportunities within the Nordic region, specifically highlighting Sweden, Iceland, Norway, Finland, and Denmark. While the firm prefers to assume the role of a lead investor in its portfolio enterprises, it also remains open to participating in co-investment ventures. On an annual basis, it endeavors to finance a maximum of five new projects. Karolinska Development AB (publ) was established in 2003 and maintains its headquarters in Stockholm, Sweden.

Market snapshot

Symbol
KDEVF
Price
$0.26
Day change
0.00%
Market cap
$75.3M
P/E ratio
-0.65x
52-week range
0.2576-0.61328
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Biostage, Inc. (BSTG)
  • Ecofibre Limited (EOFBY)
  • E-therapeutics Plc (ETXPF)
  • Herantis Pharma Oyj (HRPMF)
  • Kiaro Holdings Corp. (KIARF)
  • Mindset Pharma Inc. (MSSTF)
  • Medivir AB (publ) (MVRBF)
  • Abliva AB (publ) (NEVPF)

Open Karolinska Development AB (publ) (KDEVF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.